Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Disease: Metabolic/Endocrinology

Categories

[Search within category]

TREATING TYPE-1 DIABETES BY PRESERVING BETA CELL FUNCTION

This invention proposes the first pharmacological treatment to prevent the onset of Type I diabetes by preventing beta cell destruction. 

Generation Of Human Beta Cell Equivalents From Pluripotent Stem Cells In Vitro

This invention describes a robust method to generate functional human beta cell equivalents from pluripotent stem cells in vitro for wide applications in basic research, drug and toxicology screens and as a diabetes cell therapy.

Novel Compounds Targeting LRH-1 for Treatment of Inflammatory Bowel Disease, Type II Diabetes, Triple Negative Breast Cancer & Pancreatic Cancer

This technology contains a method for modulating the activity of the nuclear receptor LRH-1 with identified small molecule compounds that may be developed to treat inflammatory bowel disease, Type II diabetes, triple negative breast cancer and pancreatic cancer.

SALT-SPARING UREA TRANSPORT INHIBITOR DIURETICS FOR TREATMENT OF CARDIOVASCULAR AND RENAL DISORDERS

Therapeutic inhibitors of Urea Transporter A (UT-A) as highly effective diuretics with reduced risk of cardiac and neurological side effects for treatment of cardiovascular and renal disorders

Knockout Mouse Lacking Diacylglycerol Acyltransferase-1 (DGAT-1) Activity; Gene Encoding DGAT-1

Diacylglycerol acyltransferase-1 (DGAT-1) is an enzyme involved in triglyceride synthesis.  Inhibitors of DGAT-1 are currently in clinical trials as treatments for diabetes and obesity.

Small Molecule Therapy for Obesity, Dyslipidemia, and Metabolic Disease

  BACKGROUND: Cardiovascular disorders are leading causes of death worldwide and products have been developed to treat several of their addressable risk factors. Today’s market for anti-hypertensive agents is $35 billion and dyslipidemia treatments is $30 billion. While these therapies have been effective in the majority of patients in lowering blood pressure and LDL (low-density lipoprotein), they do not address other major cardiovascular risk factors such as obesity, liproprotein (a), HDL (high-density lipoprotein), and triglyceride levels. There is an unmet need for new agents that can be used alone or in combination with existing therapies to address these more elusive risk factors.   DESCRIPTION: Researchers at University of California San Francisco and Oregon Health Sciences University have discovered a new class of thyroid hormone metabolites. The most potent of these, 3-iodothyronamine, has been shown in animal studies to completely switch fuel utilization away from carbohydrates and toward lipids. In single dose hamster studies this lipid-burning effect was sustained for 24 hours, several hours after the compound had been excreted. Further studies showed both reduced LDL and significant weight loss that was selective for fat mass vs. lean mass. 3-iodothyronamine is known to be an endogenous chemical derivative of thyroid hormone, a key hormone in regulating basal metabolic rate, protein synthesis, bone growth, neuronal maturation, and metabolism of lipids and carbohydrates.

IMPROVED GENE TRANSFER AND WOUND HEALING

Brief description not available

NOVEL ANTIGEN TARGETS IN AUTOIMMUNE DISEASES (LUPUS AND TYPE I DIABETES) USEFUL FOR VACCINE DEVELOPMENT AND TREATMENT

UCSF investigators have identified novel antigens against which immune responses are induced in patients with SLE and type I diabetes. Using a proteomic approach, in addition to detecting autoantibodies to known SLE- or diabetes-associated antigens, the UCSF investigators also identified novel self-antigens that are also associated with the respective disease state. These results could provide novel approaches to the diagnosis and assessment of each of these autoimmune diseases

GENETIC MUTATIONS PREDICTIVE OF TYPE 2 DIABETES

Brief description not available

  • Go to Page: